Opthea Appoints Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor

Global retina expert joins to support sozinibercept development and launch preparationMELBOURNE, Australia, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT, “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced the appointment of Arshad M. Khanani, MD, MA, FASRS, as Chief Medical Advisor. An internationally recognized retina specialist and clinical scientist, Dr. Khanani i

Related Keywords

University Of Nevada ,Nevada ,United States ,Australia ,Melbourne ,Victoria ,American ,Frederic Guerard ,Arshadm Khanani ,Rudi Michelson ,Macula Society ,Opthea Limited ,Reno School Of Medicine ,Monsoon Communications ,American Society Of Retina Specialists ,Fellowship At Sierra Eye Associates ,Exchange Commission ,Wilmer Eye Institute At Johns Hopkins University ,Clinical Research ,Nasdaq ,Astellas Company ,Sierra Eye Associates ,Linkedin ,Retina Society ,Investment In Biotechnology Companies ,Company Media Enquiries ,Chief Medical ,Managing Partner ,Clinical Associate Professor ,Reno School ,Chief Medical Advisor ,Chief Executive Officer ,Clinical Trials ,Senior Honor Award ,American Society ,Retina Specialists ,Young Investigator Award ,Ernst Bodenheimer Memorial Lecture ,Wilmer Eye Institute ,Johns Hopkins ,Securities Litigation Reform Act ,Annual Report ,Media Enquiries ,Principal Investigator ,Dhanani ,Retinal Diseases ,Iopharmaceutical Company ,